Immutep Ltd (STU:YP1B)
€ 0.174 0.012 (7.41%) Market Cap: 260.89 Mil Enterprise Value: 149.39 Mil PE Ratio: 9,999.00 PB Ratio: 2.23 GF Score: 39/100

Immutep Ltd ShareCafe Hidden Gems Webinar Transcript

Jun 26, 2023 / NTS GMT
Release Date Price: €0.162869 (-1.80%)
Marc Voigt
Immutep Limited - Executive Director & CEO

Yeah, thank you, Paul. And it's an early hour, but never too early to get up and to present you, of course. So thank you very much for the opportunity, and thank you, everyone for joining. On the next slide is my forward-looking statement. And here you see a few key highlights in terms of Immutep . First of all, we are a company which is focusing on the patient's immune system. We are active in oncology as well as autoimmune diseases.

In oncology, you, of course, would like to have an active immune system actively fighting cancer. And in autoimmune diseases, you would like to bring it back to the right level to the right level of control. And we are actually worldwide leading in terms of luxury, it's a specific immune checkpoint, but little trigger in your immune system with which you can up or down modulate your immune system and your immune cells.

We have compelling clinical data. So we are an R&D focused company. We have a number of different partnerships with the big industry. And as an industry, as an every industry, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot